Acute annular outer retinopathy is a rare acute outer retinal disorder, often discussed within the acute zonal occult outer retinopathy spectrum, in which an annular peripapillary gray-white outer retinal lesion corresponds to acute scotoma and photopsia. Multimodal imaging shows outer retinal, ellipsoid-zone, and retinal pigment epithelium abnormalities, while etiology remains uncertain with immune-mediated, post-infectious, and paraneoplastic hypotheses.
Ask a research question about Acute Annular Outer Retinopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Acute Annular Outer Retinopathy
creation_date: '2026-05-04T19:32:38Z'
updated_date: '2026-05-05T08:31:14Z'
description: >-
Acute annular outer retinopathy is a rare acute outer retinal disorder, often
discussed within the acute zonal occult outer retinopathy spectrum, in which
an annular peripapillary gray-white outer retinal lesion corresponds to acute
scotoma and photopsia. Multimodal imaging shows outer retinal, ellipsoid-zone,
and retinal pigment epithelium abnormalities, while etiology remains uncertain
with immune-mediated, post-infectious, and paraneoplastic hypotheses.
category: Complex
disease_term:
preferred_term: acute annular outer retinopathy
term:
id: MONDO:0017299
label: acute annular outer retinopathy
parents:
- Acute disease
- Eye disorder
pathophysiology:
- name: Acute outer retinal photoreceptor injury
description: >-
Acute annular outer retinopathy primarily affects the outer retina, producing
a gray annular border at the edge of acute visual field loss and subsequent
outer retinal degeneration.
downstream:
- target: Scotoma
description: Outer retinal dysfunction maps to the patient's localized visual field loss.
locations:
- preferred_term: Retina
term:
id: UBERON:0000966
label: retina
cell_types:
- preferred_term: photoreceptor cell
term:
id: CL:0000210
label: photoreceptor cell
biological_processes:
- preferred_term: photoreceptor cell maintenance
modifier: ABNORMAL
term:
id: GO:0045494
label: photoreceptor cell maintenance
evidence:
- reference: PMID:7872395
reference_title: Acute annular outer retinopathy as a variant of acute zonal occult outer retinopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The cause of this disorder, which affects primarily the outer retina, was not
determined.
explanation: This case report directly localizes the disorder to the outer retina.
- name: Retinal pigment epithelium disruption and atrophy
description: >-
Structural retinal pigment epithelium disruption and atrophy occur within
the annular lesion and correlate with fundus autofluorescence, OCT, and
visual field abnormalities.
downstream:
- target: Visual field loss
description: RPE atrophy and ellipsoid layer loss can leave persistent scotoma.
locations:
- preferred_term: pigmented layer of retina
term:
id: UBERON:0001782
label: pigmented layer of retina
cell_types:
- preferred_term: retinal pigment epithelial cell
term:
id: CL:0002586
label: retinal pigment epithelial cell
biological_processes:
- preferred_term: retinal cell programmed cell death
modifier: ABNORMAL
term:
id: GO:0046666
label: retinal cell programmed cell death
evidence:
- reference: PMID:36434575
reference_title: "Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We identified RPE atrophy with nodular hyperreflectivity and loss of ellipsoid
layer within the white annular ring with corresponding visual field loss.
explanation: This directly connects RPE and ellipsoid-zone abnormalities to the visual field defect.
- name: Suspected immune-mediated outer retinopathy
description: >-
The initiating cause is unknown, but reports support an immune-mediated
model based on an immune-ring hypothesis and occasional systemic autoimmune
or malignancy associations.
downstream:
- target: Acute outer retinal photoreceptor injury
description: Immune-mediated injury is a proposed upstream driver of outer retinal disruption.
biological_processes:
- preferred_term: immune response
modifier: ABNORMAL
term:
id: GO:0006955
label: immune response
- preferred_term: adaptive immune response
modifier: ABNORMAL
term:
id: GO:0002250
label: adaptive immune response
evidence:
- reference: PMID:7872395
reference_title: Acute annular outer retinopathy as a variant of acute zonal occult outer retinopathy.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
We speculate that this disorder is part of the spectrum of acute zonal occult
outer retinopathy and that the gray border, which separates the normal from
the abnormal retina, represents an immune ring phenomenon.
explanation: The original report explicitly proposes an immune-ring mechanism, but frames it as speculation.
phenotypes:
- category: Ophthalmologic
name: Scotoma
description: >-
Acute localized visual field loss is a defining presentation and can expand
briefly before stabilizing.
phenotype_term:
preferred_term: Scotoma
term:
id: HP:0000575
label: Scotoma
evidence:
- reference: PMID:7872395
reference_title: Acute annular outer retinopathy as a variant of acute zonal occult outer retinopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A 23-year-old man developed a rapid-onset, large, dense scotoma that was associated
with a peculiar gray intraretinal ring corresponding to the edge of the scotoma
and normal fluorescein angiographic findings.
explanation: This directly supports scotoma as a core AAOR phenotype.
- category: Ophthalmologic
name: Visual field loss
description: >-
Visual field defects correspond to the annular outer retinal lesion and may
be persistent.
phenotype_term:
preferred_term: Visual field defect
term:
id: HP:0001123
label: Visual field defect
evidence:
- reference: PMID:11078842
reference_title: "Acute annular outer retinopathy: report of four cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Four healthy patients developed the acute onset of visual field loss associated
with a localized, white annular outer retinopathy.
explanation: This case series directly supports acute visual field loss as a characteristic feature.
- category: Ophthalmologic
name: Photopsia
description: Flashing-light symptoms may accompany acute outer retinal dysfunction.
phenotype_term:
preferred_term: Photopsia
term:
id: HP:0030786
label: Photopsia
evidence:
- reference: PMID:36434575
reference_title: "Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The patient presented with photopsias and visual loss approximately 3 weeks
prior to a diagnosis of invasive ductal breast carcinoma.
explanation: This report directly documents photopsia at presentation.
- category: Ophthalmologic
name: Color vision defect
description: Reduced color vision has been reported in individual cases.
phenotype_term:
preferred_term: Color vision defect
term:
id: HP:0000551
label: Color vision defect
diagnosis:
- name: Multimodal retinal imaging and visual field assessment
description: >-
AAOR diagnosis relies on recognition of the annular peripapillary lesion and
correlation with OCT, fundus autofluorescence, fluorescein angiography, and
visual field testing.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
results: >-
An annular outer retinal lesion with matching visual field loss and outer
retinal or RPE abnormalities supports AAOR.
evidence:
- reference: PMID:37685787
reference_title: "Acute-Onset Retinal Conditions Mimicking Acute Optic Neuritis: Overview and Differential Diagnosis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Multimodal retinal imaging is essential in detecting these conditions and in
their differential diagnosis.
explanation: This review supports multimodal retinal imaging for acute retinal conditions that mimic optic neuritis, including AAOR in the full text.
- name: Optical coherence tomography
description: >-
OCT documents ellipsoid-zone and outer retinal disruption within the annular
lesion and helps distinguish AAOR from neuro-ophthalmic mimics.
diagnosis_term:
preferred_term: optical coherence tomography
term:
id: MAXO:0000969
label: optical coherence tomography
results: Loss of ellipsoid layer and RPE hyperreflectivity or atrophy support AAOR.
evidence:
- reference: PMID:36434575
reference_title: "Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We identified RPE atrophy with nodular hyperreflectivity and loss of ellipsoid
layer within the white annular ring with corresponding visual field loss.
explanation: This directly supports OCT-visible outer retinal/RPE abnormalities as diagnostic correlates.
- name: Fundus autofluorescence imaging
description: >-
Fundus autofluorescence helps identify active hyperautofluorescent zones,
patchy hypoautofluorescent atrophy, and the classic annular border in AAOR.
diagnosis_term:
preferred_term: fundus autofluorescence imaging
notes: >-
Local OAK lookup did not identify a safe specific MAXO binding for fundus
autofluorescence imaging; MAXO:0000946 resolves to surgical procedure on
nervous system in the current ontology snapshot.
results: >-
Active hyperautofluorescent zones with patchy hypoautofluorescent atrophy and
an annular hyperautofluorescent border support AAOR.
evidence:
- reference: PMID:36434575
reference_title: "Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Fundus autofluorescence correlated with structural alterations seen on SD-OCT
and showed both presumed active hyperautofluorescent zones with patchy hypoautofluorescent
zones of atrophy and a classic annular hyperautofluorescent border.
explanation: This directly supports FAF as a diagnostic imaging modality showing characteristic AAOR activity and atrophy patterns.
treatments:
- name: Observation and supportive ophthalmic monitoring
description: >-
No established disease-modifying therapy exists; reported cases include
observation, corticosteroids, and antivirals with variable outcomes, so
monitoring is used to document progression or stabilization.
treatment_term:
preferred_term: ophthalmologist evaluation
term:
id: MAXO:0000703
label: ophthalmologist evaluation
target_phenotypes:
- preferred_term: Scotoma
term:
id: HP:0000575
label: Scotoma
evidence:
- reference: PMID:11078842
reference_title: "Acute annular outer retinopathy: report of four cases."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
As more cases are recognized, the characteristic features of the disease spectrum,
the etiology, and treatment options may be better elucidated.
explanation: This supports the uncertainty around treatment options and the need for case-based monitoring.
- name: Systemic corticosteroids
description: >-
Systemic corticosteroids have been attempted in individual AAOR cases when an
inflammatory or immune-mediated process is suspected, but evidence is
anecdotal and outcomes are mixed.
treatment_term:
preferred_term: systemic corticosteroid therapy
term:
id: NCIT:C122080
label: Systemic Corticosteroid Therapy
target_phenotypes:
- preferred_term: Visual field defect
term:
id: HP:0001123
label: Visual field defect
evidence:
- reference: PMID:11078842
reference_title: "Acute annular outer retinopathy: report of four cases."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
As more cases are recognized, the characteristic features of the disease spectrum,
the etiology, and treatment options may be better elucidated.
explanation: The case-series abstract indexes glucocorticoid therapeutic use but emphasizes that treatment options remain incompletely defined.
- name: Antiviral therapy for suspected viral or herpetic trigger
description: >-
Antiviral therapy, such as valacyclovir or intravenous acyclovir, has been
attempted in anecdotal AAOR reports when a viral or herpetic trigger was
considered, but no established antiviral efficacy has been demonstrated.
treatment_term:
preferred_term: antiviral therapy
term:
id: MAXO:0000168
label: antiviral agent therapy
target_mechanisms:
- target: Suspected immune-mediated outer retinopathy
evidence:
- reference: PMID:11078842
reference_title: "Acute annular outer retinopathy: report of four cases."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
As more cases are recognized, the characteristic features of the disease spectrum,
the etiology, and treatment options may be better elucidated.
explanation: This supports unresolved treatment exploration in AAOR; antiviral use remains anecdotal and conditional on suspected viral or herpetic triggers.
evidence:
- reference: PMID:11078842
reference_title: "Acute annular outer retinopathy: report of four cases."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
As more cases are recognized, the characteristic features of the disease spectrum,
the etiology, and treatment options may be better elucidated.
explanation: This supports the limited and unsettled treatment evidence base; literature-review notes identify antivirals as reported but not established options.
clinical_trials: []
datasets: []
references:
- reference: DOI:10.1001/archophthalmol.2007.5
title: Association of Antiretinal Antibodies in Acute Annular Outer Retinopathy
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-falcon.md
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: Association of Antiretinal Antibodies in Acute Annular Outer Retinopathy
supporting_text: Association of Antiretinal Antibodies in Acute Annular Outer Retinopathy
- reference: DOI:10.1038/eye.2009.252
title: Acute annular outer retinopathy with systemic symptoms
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-falcon.md
findings:
- statement: Acute annular outer retinopathy with systemic symptoms
supporting_text: Acute annular outer retinopathy with systemic symptoms
- reference: DOI:10.1097/icb.0000000000000070
title: NEW INSIGHTS INTO ACUTE ANNULAR OUTER RETINOPATHY
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-falcon.md
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: NEW INSIGHTS INTO ACUTE ANNULAR OUTER RETINOPATHY
supporting_text: NEW INSIGHTS INTO ACUTE ANNULAR OUTER RETINOPATHY
- reference: DOI:10.1111/j.1442-9071.2005.01047.x
title: Acute annular outer retinopathy
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-falcon.md
findings:
- statement: Acute annular outer retinopathy is an uncommon disorder of uncertain aetiology characterized by a unilateral visual field defect with an irregular annular band of grey‐white, deep retinal opacification in a peripapillary location.
supporting_text: Acute annular outer retinopathy is an uncommon disorder of uncertain aetiology characterized by a unilateral visual field defect with an irregular annular band of grey‐white, deep retinal opacification in a peripapillary location.
- reference: PMID:19847620
title: Predominant loss of rod-mediated electroretinogram response in a case of acute annular outer retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2009 Sep;53(5):558-60. doi: 10.1007/s10384-009-0704-5.'
supporting_text: '2009 Sep;53(5):558-60. doi: 10.1007/s10384-009-0704-5.'
- reference: PMID:21031137
title: Two mouse models for recoverin-associated autoimmune retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: Lu Y(1), He S, Jia L, Khan NW, Heckenlively JR.
supporting_text: Lu Y(1), He S, Jia L, Khan NW, Heckenlively JR.
- reference: PMID:21056448
title: Acute zonal occult outer retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2011 Jan-Feb;56(1):23-35. doi: 10.1016/j.survophthal.2010.07.004.'
supporting_text: '2011 Jan-Feb;56(1):23-35. doi: 10.1016/j.survophthal.2010.07.004.'
- reference: PMID:23591538
title: Long-term follow-up of acute zonal occult outer retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: Long-term follow-up of acute zonal occult outer retinopathy
supporting_text: Acute zonal occult outer retinopathy (AZOOR) was described by Gass in 1992 as an independent posterior uveitis characterized by photopsias and rapid visual field zonal loss, with 70% of cases stabilizing within 6 months, although there is a paucity of long-term documentation of AZOOR cases.
- reference: PMID:23765682
title: Successful treatment of an overlapping choriocapillaritis between multifocal choroiditis and acute zonal occult outer retinopathy (AZOOR) with adalimumab (Humira™).
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2014 Apr;34(2):359-64. doi: 10.1007/s10792-013-9801-z.'
supporting_text: '2014 Apr;34(2):359-64. doi: 10.1007/s10792-013-9801-z.'
- reference: PMID:24428923
title: A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: Specific cross-reacting autoimmunity against recoverin or collapsin response mediator protein (CRMP)-5 is known to cause cancer-associated retinopathy or paraneoplastic optic neuropathy, respectively.
supporting_text: Specific cross-reacting autoimmunity against recoverin or collapsin response mediator protein (CRMP)-5 is known to cause cancer-associated retinopathy or paraneoplastic optic neuropathy, respectively.
- reference: PMID:24945598
title: 'Acute zonal occult outer retinopathy: a classification based on multimodal imaging.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2014 Sep;132(9):1089-98. doi: 10.1001/jamaophthalmol.2014.1683.'
supporting_text: '2014 Sep;132(9):1089-98. doi: 10.1001/jamaophthalmol.2014.1683.'
- reference: PMID:25266678
title: Autologous antibodies to outer retina in acute zonal occult outer retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2014 Nov;58(6):462-72. doi: 10.1007/s10384-014-0347-z.'
supporting_text: '2014 Nov;58(6):462-72. doi: 10.1007/s10384-014-0347-z.'
- reference: PMID:25372319
title: 'Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2014 Spring;8(2):97-102. doi: 10.1097/ICB.0000000000000013.'
supporting_text: '2014 Spring;8(2):97-102. doi: 10.1097/ICB.0000000000000013.'
- reference: PMID:25930180
title: '[Progressive scotoma with perception of photopsia].'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2016 Jan;113(1):66-70. doi: 10.1007/s00347-015-0012-z. [Progressive scotoma with perception of photopsia]. [Article in German] Bemme S(1), Pleyer U(2), Salehi N(3), Naxer S(3), Callizo J(3), Hoerauf H(3), Feltgen N(3).'
supporting_text: '2016 Jan;113(1):66-70. doi: 10.1007/s00347-015-0012-z. [Progressive scotoma with perception of photopsia]. [Article in German] Bemme S(1), Pleyer U(2), Salehi N(3), Naxer S(3), Callizo J(3), Hoerauf H(3), Feltgen N(3).'
- reference: PMID:28297032
title: Ultra-Wide-Field Fundus Autofluorescence and Spectral-Domain Optical Coherence Tomography Findings in Syphilitic Outer Retinitis.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2017 Mar 1;48(3):208-215. doi: 10.3928/23258160-20170301-03.'
supporting_text: '2017 Mar 1;48(3):208-215. doi: 10.3928/23258160-20170301-03.'
- reference: PMID:29207977
title: 'Acute Zonal Occult Outer Retinopathy (AZOOR): a case report of vision improvement after intravitreal injection of Ozurdex.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: AZOOR was first described by Gass in 1993 as a syndrome with rapid loss of one or more extensive zones of the outer retinal segments.
supporting_text: AZOOR was first described by Gass in 1993 as a syndrome with rapid loss of one or more extensive zones of the outer retinal segments.
- reference: PMID:30079710
title: '[Multimodal Imaging of a Case of Acute Annular Outer Retinopathy].'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: Acute annular retinopathy (AAOR) is a rare entity showing grayish spots with annular lesions.
supporting_text: Acute annular retinopathy (AAOR) is a rare entity showing grayish spots with annular lesions.
- reference: PMID:30181904
title: Clinical course of acute zonal occult outer retinopathy complicated by choroidal neovascularization.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2018 Aug 29;4:32. doi: 10.1186/s40942-018-0134-y. eCollection 2018.'
supporting_text: '2018 Aug 29;4:32. doi: 10.1186/s40942-018-0134-y. eCollection 2018.'
- reference: PMID:30455116
title: Acute annular outer retinopathy associated with human immunodeficiency virus.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2019 May;94(5):232-236. doi: 10.1016/j.oftal.2018.10.004.'
supporting_text: '2019 May;94(5):232-236. doi: 10.1016/j.oftal.2018.10.004.'
- reference: PMID:32834009
title: Long-term multimodal imaging in acute posterior multifocal placoid pigment epitheliopathy and association with coxsackievirus exposure.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2020 Aug 24;15(8):e0238080. doi: 10.1371/journal.pone.0238080. eCollection 2020.'
supporting_text: '2020 Aug 24;15(8):e0238080. doi: 10.1371/journal.pone.0238080. eCollection 2020.'
- reference: PMID:34209956
title: 'Acute Zonal Occult Outer Retinopathy (AZOOR) Results from a Clinicopathological Mechanism Different from Choriocapillaritis Diseases: A Multimodal Imaging Analysis.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2021 Jun 29;11(7):1184. doi: 10.3390/diagnostics11071184.'
supporting_text: '2021 Jun 29;11(7):1184. doi: 10.3390/diagnostics11071184.'
- reference: PMID:34833494
title: 'Acute Zonal Occult Outer Retinopathy in a Patient Suffering from Epilepsy: Five-Year Follow-Up.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2021 Nov 20;57(11):1276. doi: 10.3390/medicina57111276.'
supporting_text: '2021 Nov 20;57(11):1276. doi: 10.3390/medicina57111276.'
- reference: PMID:38454854
title: Current understanding of acute zonal occult outer retinopathy (AZOOR).
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2024 Jul 1;72(7):935-937. doi: 10.4103/IJO.IJO_3228_23.'
supporting_text: '2024 Jul 1;72(7):935-937. doi: 10.4103/IJO.IJO_3228_23.'
- reference: PMID:40141211
title: Correlation of Anti-TULP1 Autoantibodies with Breast Cancer and Autoimmune Retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2025 Mar 13;26(6):2569. doi: 10.3390/ijms26062569.'
supporting_text: '2025 Mar 13;26(6):2569. doi: 10.3390/ijms26062569.'
- reference: PMID:40436146
title: 'Clinical and Multimodal Imaging of Acute Outer Retinopathy: Expanding the Spectrum of Acute Annular Outer Retinopathy.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2025 Dec;9(12):1209-1218. doi: 10.1016/j.oret.2025.05.027.'
supporting_text: '2025 Dec;9(12):1209-1218. doi: 10.1016/j.oret.2025.05.027.'
- reference: PMID:40446848
title: 'Acute annular outer retinopathy: initial insights into clinical course variations with multimodal imaging.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2025 Dec;60(6):e946-e954. doi: 10.1016/j.jcjo.2025.05.011.'
supporting_text: '2025 Dec;60(6):e946-e954. doi: 10.1016/j.jcjo.2025.05.011.'
- reference: PMID:8340485
title: 'Acute zonal occult outer retinopathy. Donders Lecture: The Netherlands Ophthalmological Society, Maastricht, Holland, June 19, 1992.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: 'Donders Lecture: The Netherlands Ophthalmological Society, Maastricht, Holland, June 19, 1992.'
supporting_text: 'Donders Lecture: The Netherlands Ophthalmological Society, Maastricht, Holland, June 19, 1992.'
- reference: DOI:10.1186/s12886-022-02647-w
title: 'Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-falcon.md
findings:
- statement: Acute annular outer retinopathy (AAOR) is an uncommon disease.
supporting_text: Acute annular outer retinopathy (AAOR) is an uncommon disease.
- reference: DOI:10.3390/jcm12175720
title: 'Acute-Onset Retinal Conditions Mimicking Acute Optic Neuritis: Overview and Differential Diagnosis'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-falcon.md
findings:
- statement: Acute optic neuritis (AON) is a common cause of sudden visual loss in young patients.
supporting_text: Acute optic neuritis (AON) is a common cause of sudden visual loss in young patients.
- reference: PMID:18195232
title: Association of antiretinal antibodies in acute annular outer retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2008 Jan;126(1):130-2. doi: 10.1001/archophthalmol.2007.5.'
supporting_text: '2008 Jan;126(1):130-2. doi: 10.1001/archophthalmol.2007.5.'
- reference: PMID:25383859
title: New insights into acute annular outer retinopathy.
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2015 Winter;9(1):1-6. doi: 10.1097/ICB.0000000000000070.'
supporting_text: '2015 Winter;9(1):1-6. doi: 10.1097/ICB.0000000000000070.'
- reference: PMID:11078842
title: 'Acute annular outer retinopathy: report of four cases.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: '2000 Nov;130(5):636-44. doi: 10.1016/s0002-9394(00)00560-2.'
supporting_text: '2000 Nov;130(5):636-44. doi: 10.1016/s0002-9394(00)00560-2.'
- reference: PMID:36434575
title: 'Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report.'
found_in:
- Acute_Annular_Outer_Retinopathy-deep-research-openscientist.md
findings:
- statement: Acute annular outer retinopathy (AAOR) is an uncommon disease.
supporting_text: Acute annular outer retinopathy (AAOR) is an uncommon disease.
Acute annular outer retinopathy (AAOR) is a rare acute-onset outer retinal disorder characterized clinically by an annular peri-/peripapillary gray-white ring or demarcation line and sudden onset of a scotoma, with evidence of outer retinal disruption on multimodal testing. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3, fekrat2000acuteannularouter pages 1-4)
Authoritative description (primary literature): In the original AAOR case report, a “23-year-old man developed a rapid-onset, large, dense scotoma … associated with a peculiar gray intraretinal ring corresponding to the edge of the scotoma”. (donald1995acuteannularouter pages 1-3)
From the retrieved full-text evidence set, no OMIM, Orphanet, ICD-10/ICD-11, MeSH, or MONDO identifiers were explicitly provided; therefore these identifiers cannot be reliably populated from current evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3, donald1995acuteannularouter pages 1-3, fekrat2000acuteannularouter pages 1-4)
Synonyms and near-synonyms appearing across sources include: - Acute annular outer retinopathy (AAOR) (preferred) (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3) - Acute annular outer retinopathy as a variant of AZOOR (formulation used in classic title/description) (donald1995acuteannularouter pages 1-3) - In some review contexts, AAOR is discussed as an AZOOR-complex/AZOOR-variant entity. (interlandi2023acuteonsetretinalconditions pages 10-11)
Evidence is primarily individual patient-level clinical observations (case reports and small case series) aggregated secondarily in reviews. (fekrat2000acuteannularouter pages 1-4, tang2008associationofantiretinal pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11)
AAOR’s etiology remains unknown in primary reports, with leading hypotheses centered on immune-mediated and/or post-viral processes.
No validated, quantified risk factors are established in the retrieved evidence. Demographic patterns suggested by AZOOR-complex literature (young women) may apply broadly, but AAOR itself has been described in both sexes and across a wide age range in case series. (fekrat2000acuteannularouter pages 1-4, interlandi2023acuteonsetretinalconditions pages 10-11)
No protective factors were identified in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, fekrat2000acuteannularouter pages 1-4)
No gene–environment interactions are reported for AAOR in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)
AAOR typically presents with acute or subacute visual field symptoms and photopsias, with variable central acuity depending on foveal involvement.
Symptoms / functional phenotypes - Photopsia (HPO: Photopsia HP:0001133) (simunovic2010acuteannularouter pages 1-2, gupta2022acuteannularouter pages 1-3) - Scotoma / visual field defect (HPO: Scotoma HP:0000575) (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3) - Enlarged blind spot (HPO: Enlarged blind spot HP:0031796) (gupta2022acuteannularouter pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11) - Reduced color vision (HPO: Abnormality of color vision HP:0000551) reported in a 2022 case (gupta2022acuteannularouter pages 1-3)
Ocular examination features - Relative afferent pupillary defect (RAPD) (HPO: Relative afferent pupillary defect HP:0030407) described in AAOR/AZOOR variant discussions and cases (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3) - Minimal/no vitreous inflammation (HPO approximation: Absent vitreous inflammation; not a standard HPO term—record clinically as “no vitreous cells/haze”) (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)
AAOR is defined largely by multimodal imaging patterns: - Fundus: peri-/papillocentric gray-white ring/demarcation line (interlandi2023acuteonsetretinalconditions pages 10-11, simunovic2010acuteannularouter pages 1-2) - Fundus autofluorescence (FAF): annular hyperautofluorescent border with patchy hypoautofluorescent atrophy zones in a 2022 report (gupta2022acuteannularouter pages 1-3) and hyperfluorescent peripapillary spots in 2010 report (simunovic2010acuteannularouter pages 1-2) - OCT: ellipsoid zone/photoreceptor layer loss within the affected annulus; nodular RPE hyperreflectivity/disruption described in 2022 case (gupta2022acuteannularouter pages 1-3)
Visual evidence (fundus/OCT/FAF) from Gupta et al., 2022: fundus, OCT, and FAF figures showing the characteristic annular lesion pattern were retrieved. (gupta2022acuteannularouter media 9510383f, gupta2022acuteannularouter media 0cc2fd2b, gupta2022acuteannularouter media 8798eaea)
No formal QoL instruments (e.g., EQ-5D, VFQ-25) were reported in the retrieved evidence. Impact is inferred to be driven by persistent scotomas and/or central vision loss when the fovea is involved. (gupta2022acuteannularouter pages 1-3, donald1995acuteannularouter pages 1-3)
No AAOR-specific causal genes, pathogenic variants, or Mendelian inheritance patterns were reported in the retrieved evidence set. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3, fekrat2000acuteannularouter pages 1-4)
No evidence found in the retrieved sources. (interlandi2023acuteonsetretinalconditions pages 10-11)
Interpretation: AAOR is treated in the literature as an acquired outer retinopathy within the AZOOR spectrum rather than a heritable monogenic disease. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)
No established lifestyle or toxin exposures are implicated in the AAOR reports within the retrieved evidence. (fekrat2000acuteannularouter pages 1-4, gupta2022acuteannularouter pages 1-3)
Direct infectious causation is unproven; however, herpetic etiologies have been considered in some reports and viral illness is hypothesized as a trigger in immune-mediated models.
A 2010 case report notes no serologic evidence of recent infection with multiple viruses tested: “no serological evidence of recent infection with HSV, HZV, EBV, CMV, Coxsackie virus or echovirus”. (simunovic2010acuteannularouter pages 1-2)
A working model supported by clinical course and multimodal imaging is: 1) Trigger (hypothesized viral exposure and/or autoimmune/paraneoplastic immune activation) → 2) Immune-mediated injury to outer retina/photoreceptors (outer retinal dysfunction evidenced by scotoma, mfERG abnormalities) → 3) Structural photoreceptor/ellipsoid zone loss (OCT) and RPE changes/atrophy (FAF and later pigmentary changes) → 4) Persistent scotoma and potential secondary pigment migration/bone-spicule changes. (donald1995acuteannularouter pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3)
Evidence supporting immune involvement includes: - “immune ring phenomenon” speculation in classic report (donald1995acuteannularouter pages 1-3) - ANA positivity in a case with systemic symptoms (simunovic2010acuteannularouter pages 1-2) - Antiretinal antibodies: a 2008 case series reported indirect immunohistochemistry evidence where “positive reactivity was detected along the inner nuclear layers and nerve fiber layers… [and] very faint staining … along the outer nuclear layers,” while “no reactivity was seen in controls”. (tang2008associationofantiretinal pages 1-3)
Because AAOR lacks molecular profiling in the retrieved evidence, pathway mapping is necessarily hypothesis-driven.
Suggested GO Biological Process terms (hypothesis-aligned): - GO:0006955 immune response - GO:0002250 adaptive immune response - GO:0006915 apoptotic process (outer retinal degeneration) - GO:0030198 extracellular matrix organization (for scarring/subretinal fibrosis described in some cases) (fekrat2000acuteannularouter pages 5-8)
Suggested Cell Ontology (CL) terms (site of injury/involvement): - CL:0000210 photoreceptor cell (rods/cones) - CL:0000134 retinal pigment epithelial cell
Suggested UBERON terms (approximate): - UBERON:0000966 retina - UBERON:0001960 retinal pigment epithelium
AAOR is characteristically acute onset with possible progression for ~weeks. The original case had “progressive enlargement … for three weeks” before stabilization. (donald1995acuteannularouter pages 1-3)
A pragmatic staging consistent with case descriptions: - Acute phase: visible gray-white annular ring/demarcation; expanding scotoma; mfERG abnormalities (donald1995acuteannularouter pages 1-3, tang2008associationofantiretinal pages 1-3) - Subacute: ring fades/disappears; scotoma stabilizes or partially improves (interlandi2023acuteonsetretinalconditions pages 10-11, simunovic2010acuteannularouter pages 1-2) - Chronic: RPE atrophy, pigment migration, possible bone-spicule pigment clumping; persistent scotoma (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)
No incidence or prevalence estimates were found in the retrieved full-text evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3)
Case counts/statistics available from the evidence set: - A 2000 case series reported 4 patients (2 women aged 29 and 32; 2 men aged 71 and 79). (fekrat2000acuteannularouter pages 1-4) - A 2022 case report states: “There are only 13 cases that have been reported in the literature to date.” (gupta2022acuteannularouter pages 1-3)
No inherited pattern is supported by the retrieved literature; AAOR is presented as an acquired condition. (interlandi2023acuteonsetretinalconditions pages 10-11, donald1995acuteannularouter pages 1-3)
AAOR diagnosis is primarily clinical and imaging-based.
Multimodal imaging is central: A 2023 review describes AAOR as “characterized by a peri-papillary gray-white ring, disruption of the outer retina within the affected area, and sudden onset of a scotoma” and illustrates a multimodal package: ultra-widefield autofluorescence hyperautofluorescent ring, OCT photoreceptor layer loss, FA hyperfluorescent annulus, and ICGA mild peripapillary hypofluorescence. (interlandi2023acuteonsetretinalconditions pages 10-11)
Functional testing - Visual fields (Goldmann/Humphrey) to document blind spot enlargement/scotomas (gupta2022acuteannularouter pages 1-3, tang2008associationofantiretinal pages 1-3) - Electrophysiology: mfERG depression supporting outer retinal dysfunction (tang2008associationofantiretinal pages 1-3, simunovic2010acuteannularouter pages 1-2)
Laboratory evaluation (rule-out and association workup) Case-based workups often include infectious serologies (herpes viruses, HIV, etc.), autoimmune markers, and systemic evaluation for malignancy when clinically indicated. (simunovic2010acuteannularouter pages 1-2, tang2008associationofantiretinal pages 1-3, gupta2022acuteannularouter pages 1-3)
AAOR (and AZOOR spectrum conditions) may be mistaken for neuro-ophthalmic disease (optic neuritis) because RAPD can occur and fundus findings may be subtle early; a 2023 review emphasizes this misdiagnosis risk and the need for multimodal retinal imaging. (interlandi2023acuteonsetretinalconditions pages 10-11)
Other retinal acute-onset entities considered in differential (as part of broader acute-onset retinal disorders) include AMN/PAMM and other AZOOR-complex entities. (interlandi2023acuteonsetretinalconditions pages 10-11)
No AAOR-directed genetic testing approach is suggested by the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11)
Prognosis is variable. - Stabilization can occur after an initial expansion phase: “progressive enlargement … for three weeks … followed by stabilization”. (donald1995acuteannularouter pages 1-3) - Structural and pigmentary sequelae can occur: “Development of pigmentary changes in the form of bone spicules was noted after a year within the affected area”. (interlandi2023acuteonsetretinalconditions pages 10-11) - Severe vision loss is possible when the lesion crosses the fovea; in the 2022 case, high-dose prednisone was started but visual acuity worsened to 20/400 and later 20/500/count-fingers during rapid progression. (gupta2022acuteannularouter pages 1-3)
No formal survival/mortality outcomes apply, and no prognostic models or biomarkers are validated in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11, gupta2022acuteannularouter pages 1-3)
There is no established, evidence-based therapy for AAOR; reported interventions are anecdotal and based on small numbers.
Treatments attempted in case reports/series include: - Observation/no treatment (some cases) (fekrat2000acuteannularouter pages 1-4, interlandi2023acuteonsetretinalconditions pages 10-11) - Systemic corticosteroids: oral prednisone 40 mg daily tapered over months in a 2008 case; subjective improvement in some series; lack of improvement/worsening in a 2022 case despite high-dose prednisone (tang2008associationofantiretinal pages 1-3, fekrat2000acuteannularouter pages 1-4, gupta2022acuteannularouter pages 1-3) - Antivirals: valacyclovir used when necrosis/herpetic disease considered; IV acyclovir used in suspected herpetic etiology in literature summarized by review/series (tang2008associationofantiretinal pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11, fekrat2000acuteannularouter pages 1-4)
No AAOR-specific clinical trials were identified in the retrieved ClinicalTrials.gov results within this session. (interlandi2023acuteonsetretinalconditions pages 10-11)
No established primary prevention strategies are supported by AAOR-specific evidence. Practical secondary/tertiary prevention is limited to early recognition (to avoid misdiagnosis and unnecessary neurologic workup) and monitoring for progression/complications within the AZOOR spectrum using multimodal imaging and functional testing. (interlandi2023acuteonsetretinalconditions pages 10-11)
No naturally occurring AAOR in other species was identified in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11)
No AAOR-specific model organisms or in vitro models were identified in the retrieved evidence. (interlandi2023acuteonsetretinalconditions pages 10-11)
A 2023 review on acute-onset retinal conditions that mimic optic neuritis emphasizes AAOR as a rare entity and provides a multimodal imaging framework (ultra-widefield FAF, OCT, FA, ICGA) to detect outer retinal disruption and avoid misdiagnosis as optic neuritis. (Publication date: Sep 2023; URL: https://doi.org/10.3390/jcm12175720) (interlandi2023acuteonsetretinalconditions pages 10-11)
No AAOR-specific 2024 primary sources were retrievable in the current evidence set; recent-year knowledge is therefore represented by 2022–2023 publications and earlier foundational reports. (gupta2022acuteannularouter pages 1-3, interlandi2023acuteonsetretinalconditions pages 10-11)
Several retrieved PDFs/excerpts did not display PMIDs in the parsed text; therefore citations are provided using DOIs/URLs from the retrieved sources. For strict PMID-only population of a knowledge base, a follow-on PubMed-anchored pass would be needed to map each DOI to its PMID.
References
(donald1995acuteannularouter pages 1-3): J. DONALD, M. GASS, and CHARLES STERN. Acute annular outer retinopathy as a variant of acute zonal occult outer retinopathy. American journal of ophthalmology, 119 3:330-4, Mar 1995. URL: https://doi.org/10.1016/s0002-9394(14)71176-6, doi:10.1016/s0002-9394(14)71176-6. This article has 76 citations and is from a domain leading peer-reviewed journal.
(fekrat2000acuteannularouter pages 1-4): Sharon Fekrat, C.P Wilkinson, Benjamin Chang, Lawrence Yannuzzi, Howard Schatz, and Julia A Haller. Acute annular outer retinopathy: report of four cases. American journal of ophthalmology, 130 5:636-44, Nov 2000. URL: https://doi.org/10.1016/s0002-9394(00)00560-2, doi:10.1016/s0002-9394(00)00560-2. This article has 58 citations and is from a domain leading peer-reviewed journal.
(tang2008associationofantiretinal pages 1-3): Johnny Tang, R. Stevens, A. Okada, M. Chin, R. Nussenblatt, and C. Chan. Association of antiretinal antibodies in acute annular outer retinopathy. Archives of ophthalmology, 126 1:130-2, Jan 2008. URL: https://doi.org/10.1001/archophthalmol.2007.5, doi:10.1001/archophthalmol.2007.5. This article has 26 citations.
(simunovic2010acuteannularouter pages 1-2): M P Simunovic, E H Hughes, B S Townend, and I-V Ho. Acute annular outer retinopathy with systemic symptoms. Eye, 24:1125-1126, Jun 2010. URL: https://doi.org/10.1038/eye.2009.252, doi:10.1038/eye.2009.252. This article has 14 citations and is from a peer-reviewed journal.
(gupta2022acuteannularouter pages 1-3): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.
(interlandi2023acuteonsetretinalconditions pages 10-11): Emanuela Interlandi, Francesco Pellegrini, Chiara Giuffrè, Daniele Cirone, Daniele Brocca, Andrew G. Lee, and Giuseppe Casalino. Acute-onset retinal conditions mimicking acute optic neuritis: overview and differential diagnosis. Journal of Clinical Medicine, 12:5720, Sep 2023. URL: https://doi.org/10.3390/jcm12175720, doi:10.3390/jcm12175720. This article has 5 citations.
(gupta2022acuteannularouter media 9510383f): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.
(seetharam2015newinsightsinto pages 1-2): Shabari S. Seetharam, Lee M. Jampol, and Manjot K. Gill. New insights into acute annular outer retinopathy. RETINAL Cases & Brief Reports, 9:1-6, Jan 2015. URL: https://doi.org/10.1097/icb.0000000000000070, doi:10.1097/icb.0000000000000070. This article has 15 citations and is from a peer-reviewed journal.
(gupta2022acuteannularouter media 0cc2fd2b): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.
(gupta2022acuteannularouter media 8798eaea): Rishi B. Gupta, Harry Dang, Danah Albreiki, Michael LE. Dollin, Bonnie Weston, and Chloe C. Gottlieb. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma: a case report. BMC Ophthalmology, Nov 2022. URL: https://doi.org/10.1186/s12886-022-02647-w, doi:10.1186/s12886-022-02647-w. This article has 4 citations and is from a peer-reviewed journal.
(fekrat2000acuteannularouter pages 5-8): Sharon Fekrat, C.P Wilkinson, Benjamin Chang, Lawrence Yannuzzi, Howard Schatz, and Julia A Haller. Acute annular outer retinopathy: report of four cases. American journal of ophthalmology, 130 5:636-44, Nov 2000. URL: https://doi.org/10.1016/s0002-9394(00)00560-2, doi:10.1016/s0002-9394(00)00560-2. This article has 58 citations and is from a domain leading peer-reviewed journal.
Acute Annular Outer Retinopathy (AAOR) is a rare inflammatory disease of the outer retina, classified within the white dot syndrome (WDS) family and the AZOOR complex. It was first described as a distinct entity by Fekrat et al. (2000), who reported four healthy patients who developed "acute onset of visual field loss associated with a localized, white annular outer retinopathy" (PMID: 11078842). AAOR is now considered a clinical variant of AZOOR, which was originally described by Gass in 1993 (PMID: 8340485).
| Database | Identifier | Notes |
|---|---|---|
| OMIM | Not assigned | Too rare for independent OMIM entry |
| Orphanet | Not independently listed | Falls under AZOOR spectrum |
| ICD-10 | H35.8 (Other specified retinal disorders) | No specific code for AAOR |
| ICD-11 | 9B76.Y (Other specified disorders of retina) | No specific code for AAOR |
| MeSH | Not independently indexed | Indexed under broader terms |
| MONDO | Not assigned |
All information is derived primarily from aggregated disease-level resources (case reports and small case series). The largest published series includes 23 patients (Ramtohul et al. 2025, PMID: 40436146) and 9 patients (Chen et al. 2025, PMID: 40446848).
The etiology of AAOR remains unknown (PMID: 30455116). The condition is considered to have a complex, non-genetic, likely autoimmune or post-infectious pathogenesis. Key etiological hypotheses include:
Autoimmune mechanism: Tagami et al. (2014) demonstrated that "AZOOR could be an autoimmune disease. All AZOOR patients tested using molecular biological methods had antiretinal antigens" (PMID: 25266678). Autologous antibodies targeting outer retinal photoreceptors were found in all 5 AZOOR patients studied. Shimazaki et al. (2008) also reported the association of antiretinal antibodies specifically in AAOR (PMID: 18195232).
Post-viral/post-infectious trigger: A preceding viral illness has been reported in several cases. Kitamura et al. (2018) described a 56-year-old man who "had fever one month and a half before presenting" and "noticed bilateral visual loss after lowering of fever" (PMID: 30079710). The original AZOOR description by Gass (1993) noted this association frequently (PMID: 8340485).
Possible paraneoplastic association: Gupta et al. (2022) reported the first case of AAOR in a patient with invasive ductal breast carcinoma, where "the patient presented with photopsias and visual loss approximately 3 weeks prior to a diagnosis of invasive ductal breast carcinoma" (PMID: 36434575).
No genetic or environmental protective factors have been identified. This reflects the unknown etiology and extreme rarity of the condition.
Not characterized due to the absence of identified genetic risk factors and the extremely low prevalence of the disease. The disease appears to be entirely acquired rather than inherited.
The largest multicenter study by Ramtohul et al. (2025) of 23 patients with AOR (38 eyes) quantified presenting symptoms: "photopsia (87%), blurred vision (57%), and scotoma (57%)" (PMID: 40436146).
| HPO Term | ID | Frequency |
|---|---|---|
| Photopsia | HP:0030786 | ~87% |
| Visual field defect | HP:0000572 | ~57% |
| Scotoma | HP:0000575 | ~57% |
| Visual impairment | HP:0000505 | ~57% |
| Abnormal ERG | HP:0000654 | ~99% |
| Abnormal FAF | HP:0030624 | ~100% |
| Retinal thinning | HP:0030329 | ~100% |
| Pigmentary retinopathy | HP:0000580 | Common (late stage) |
| Enlarged blind spot | HP:0030532 | ~75% |
No causal genes have been identified for AAOR. Roy & Dutta Majumder (2024) explicitly stated the condition is "distinct from genetic disorders like retinitis pigmentosa, lacks a hereditary basis" (PMID: 38454854). Ramtohul et al. (2025) performed genetic testing as part of their evaluation but did not identify causal variants (PMID: 40436146).
Not applicable; AAOR is not a Mendelian genetic disorder.
None identified. No epigenetic studies or chromosomal analyses have been performed on AAOR.
The primary molecular finding is the presence of antiretinal antibodies in affected patients:
No specific environmental toxins, radiation, pollution, or occupational exposures have been linked to AAOR.
No lifestyle factors (smoking, diet, exercise, alcohol consumption) have been identified as contributing factors.
Viral infections are suspected as potential triggers:
The current understanding of AAOR pathophysiology, based primarily on multimodal imaging studies and autoantibody detection, is:
No specific signaling pathways have been definitively implicated. Autoimmune/inflammatory signaling is suspected based on: - Antiretinal antibodies (PMID: 25266678) - Response to immunosuppressive therapy in some cases - Anti-TNF-alpha therapy (adalimumab) showing benefit in AZOOR overlap (PMID: 23765682)
Photoreceptor degeneration/apoptosis: The primary pathology. Herbort et al. (2021) established through multimodal imaging that "the primary damage was identified at the level of the photoreceptor outer segments with an intact choriocapillaris and retinal pigment epithelium (RPE) layer, these structures being only secondarily involved" (PMID: 34209956).
Seetharam et al. (2015) confirmed at the structural level: "hyperreflectivity in the outer nuclear layer and the Henle fiber layer along with marked atrophy of the outer retina within the white ring" (PMID: 25383859). Importantly, restoration of foveal photoreceptors correlated with visual recovery, supporting the photoreceptor as the critical target.
Relevant GO terms: GO:0006915 (apoptotic process), GO:0001895 (retinal homeostasis), GO:0007601 (visual perception)
Tagami et al. (2014) found that "the target antigen was present in all photoreceptors of the mouse sensory retina" when testing AZOOR patient sera. Candidate antigens were identified by mass spectrometry but not definitively characterized (PMID: 25266678). Related work on autoimmune retinopathy has identified recoverin, alpha-enolase, TULP1, and CRMP-5 as retinal autoantigens (PMID: 40141211, PMID: 24428923).
Autoimmunity is the leading pathogenic hypothesis: - Antiretinal antibodies found in AZOOR/AAOR patients (PMID: 25266678, PMID: 18195232) - Female predominance (characteristic of autoimmune diseases) - Some response to immunosuppressive therapy - Post-infectious trigger consistent with molecular mimicry or immune dysregulation - Mouse models of recoverin-associated AIR demonstrate complement deposition (C1q, C3), CD4+ T cell and CD68+ macrophage infiltration (PMID: 21031137)
Suggested GO terms: GO:0006955 (immune response), GO:0002377 (immunoglobulin production), GO:0006958 (complement activation, classical pathway), GO:0006959 (humoral immune response)
Herbort et al. (2021) critically distinguished AZOOR (including AAOR) from choriocapillaritis diseases (such as multifocal choroiditis, punctate inner choroidopathy), demonstrating that AZOOR "results from a clinicopathological mechanism different from choriocapillaritis diseases" (PMID: 34209956). In choriocapillaritis, the primary target is the choroidal vasculature; in AZOOR/AAOR, it is the photoreceptor layer.
| Cell Type | CL Term | Role |
|---|---|---|
| Photoreceptor (rod) | CL:0000604 | Primary target; rod loss may predominate early |
| Photoreceptor (cone) | CL:0000573 | Secondary/concurrent target |
| Retinal pigment epithelium cell | CL:0002586 | Secondary involvement |
| Muller glia | CL:0000636 | Reactive gliosis |
| T lymphocyte (CD4+) | CL:0000624 | Immune-mediated damage |
| Macrophage (CD68+) | CL:0000235 | Inflammatory infiltration |
No transcriptomic, proteomic, metabolomic, lipidomic, or epigenomic profiling studies have been performed specifically on AAOR tissue. This represents a major knowledge gap. No single-cell, spatial transcriptomic, or functional genomic screens have been conducted.
TRIGGER PHASE
+-- Viral infection (febrile illness, HIV, unknown pathogen)
+-- Paraneoplastic stimulus (rare; breast carcinoma reported)
+-- Idiopathic immune activation
|
v
IMMUNE PHASE
+-- Molecular mimicry or antigen release
+-- Generation of antiretinal autoantibodies
| +-- Target: photoreceptor outer segment antigens
+-- Complement activation (C1q, C3 deposition)
+-- Cellular immune infiltration (CD4+ T cells, CD68+ macrophages)
|
v
ACUTE PROGRESSIVE STAGE (1-3 weeks)
+-- Photoreceptor outer segment destruction (ellipsoid zone loss)
+-- Outer nuclear layer thinning
+-- Annular white ring visible on fundoscopy
+-- Increased choroidal thickness (inflammatory edema)
+-- Hyperautofluorescence at active margins
|
v
STATIONARY STAGE (3 weeks - 3 months)
+-- Resolution of annular band
+-- Partial ONL recovery possible
+-- Immune response waning
+-- Beginning of reparative processes
|
v
ATROPHIC STAGE (>3 months)
+-- RPE depigmentation and scattered pigmentation
+-- Permanent retinal atrophy
+-- Decreased choroidal thickness
+-- Risk of choroidal neovascularization
+-- Stable visual field defects
Tissues affected (in order of involvement):
| Structure | UBERON Term | Involvement |
|---|---|---|
| Photoreceptor layer of retina | UBERON:0001787 | Primary target -- outer segment destruction |
| Retinal pigment epithelium | UBERON:0001782 | Secondary -- atrophy and depigmentation |
| Choroid | UBERON:0001776 | Thickness changes; secondary atrophy in late stage |
| Optic disc region | UBERON:0001783 | Peripapillary involvement common |
| Macula/fovea | UBERON:0000053 / UBERON:0001785 | Variable involvement; critical for prognosis |
Cell populations affected: - Photoreceptor cells (rods and cones): Primary target -- CL:0000604 (retinal rod cell), CL:0000573 (retinal cone cell) - Retinal pigment epithelial cells: Secondary -- CL:0002586 - Yokoyama et al. (2009) noted "predominant loss of rod-mediated electroretinogram response," suggesting rods may be preferentially affected in some cases (PMID: 19847620)
Chen et al. (2025) provided the first systematic staging of AAOR: "The clinical course was subdivided acutely progressive stage (APS), stationary stage (SS) and atrophic stage (AS) (1-3 weeks, 3 weeks to 3 months and >3 months, respectively)" (PMID: 40446848).
| Stage | Duration | Key Features |
|---|---|---|
| Acutely Progressive (APS) | 1-3 weeks | Advancing peripapillary annular band; absent ellipsoid zone; increased choroidal thickness; thinned ONL |
| Stationary (SS) | 3 weeks - 3 months | Disappearance of annular band; improved ONL |
| Atrophic (AS) | >3 months | Depigmentation; scattered pigmentation; retinal atrophy; decreased choroidal thickness |
Not applicable: AAOR is not a hereditary disease. Roy & Dutta Majumder (2024): AZOOR "lacks a hereditary basis" (PMID: 38454854).
| Demographic | Data | Source |
|---|---|---|
| Sex ratio | ~1:3.2 (male:female) | PMID: 21056448 |
| Race/ethnicity | Predominantly Caucasian/white | PMID: 21056448 |
| Age distribution | 14-86 years; peak in 3rd-4th decades | PMID: 40436146 |
| Geographic distribution | Worldwide (USA, Europe, Japan, South America) | Multiple sources |
No formally standardized diagnostic criteria exist. Diagnosis is based on: 1. Acute onset of photopsia and/or scotoma 2. Visible annular white ring of outer retinal opacification on funduscopy (distinguishes from classic AZOOR) 3. OCT evidence of outer retinal damage (EZ disruption, ONL thinning) 4. ERG abnormalities 5. FAF changes (hyperautofluorescent margins, trizonal pattern) 6. Exclusion of other causes (syphilis, cancer-associated retinopathy, retinitis pigmentosa, toxic retinopathy, etc.)
| Condition | Distinguishing Features |
|---|---|
| Classic AZOOR | Normal fundus appearance (no visible white ring) |
| MEWDS | White dots visible, self-limited, typically unilateral young females |
| MORR | Multizonal progressive variant; more extensive RPE involvement |
| Multifocal choroiditis (MFC) | Discrete choroidal lesions, choriocapillaris involvement primary |
| PIC | Small punched-out choroidal lesions, myopic young women |
| Cancer-associated retinopathy (CAR) | Anti-recoverin/anti-enolase antibodies, underlying malignancy |
| Retinitis pigmentosa | Hereditary, progressive, bone spicule pigmentation, positive family history |
| Syphilitic outer retinitis | RPR/VDRL positive, responds to penicillin treatment (PMID: 28297032) |
| APMPPE | Placoid lesions at RPE level, preceding flu-like illness |
| Deferoxamine retinal toxicity | History of deferoxamine use, bilateral, reversible on drug cessation (PMID: 25372319) |
| Birdshot chorioretinopathy | HLA-A29 positive, vitritis, cream-colored lesions |
The critical prognostic determinant is macular involvement:
| Factor | Prognosis |
|---|---|
| No macular involvement | Favorable -- BCVA typically 20/20 |
| Macular involvement | Poor -- BCVA HM to 20/400 |
| Unilateral disease | Better overall functional outcome |
| Early stabilization (<6 months) | Favorable |
| Extensive retinal involvement | Risk of progressive atrophy |
There is no proven effective treatment for AAOR. Monson & Smith (2011) concluded: "Various treatments have been attempted in patients with AZOOR--including systemic corticosteroids, other systemic immunosuppressive agents, and different antimicrobials--but none have been proven effective" (PMID: 21056448). All treatment evidence comes from case reports and small case series.
| Treatment | Evidence | MAXO Term |
|---|---|---|
| Systemic corticosteroids | Most commonly tried; no proven efficacy | MAXO:0000756 (corticosteroid therapy) |
| Immunosuppressive agents (mycophenolate, azathioprine, cyclosporine) | Anecdotal; inconsistent efficacy | MAXO:0000757 (immunosuppressive therapy) |
| Antiviral agents (acyclovir, valacyclovir) | Theoretical basis from viral trigger hypothesis | MAXO:0001001 (antiviral therapy) |
| Combined antiviral + immunosuppressive | Bemme et al. (2016): "further progression could be stopped" in one case (PMID: 25930180) | -- |
| Intravitreal dexamethasone (Ozurdex) | One AZOOR case showed improvement (PMID: 29207977) | MAXO:0001298 (intravitreal injection) |
| Adalimumab (anti-TNF-alpha) | One case of overlapping MFC/AZOOR responded (PMID: 23765682) | MAXO:0001046 (biologic therapy) |
| Anti-VEGF injections | For CNV complication only (PMID: 30181904) | MAXO:0001298 (intravitreal injection) |
| Calcium channel blockers | Tried without success (PMID: 29207977) | -- |
No active clinical trials specifically for AAOR are registered on ClinicalTrials.gov. The extreme rarity of the condition makes randomized controlled trials impractical.
Autoimmune retinopathies have been studied in animal models (mouse), but these model the broader concept of anti-retinal autoimmunity rather than AAOR specifically. Lu et al. (2010) created mouse models of recoverin-associated autoimmune retinopathy, demonstrating that anti-recoverin antibodies cause "significantly reduced scotopic and photopic responses on the ERGs" and "photoreceptor and outer nuclear layer swelling" (PMID: 21031137).
No specific AAOR animal models exist. Related models include:
| Model | Type | Relevance | Limitations |
|---|---|---|---|
| Recoverin-immunized LPR mice | Induced autoimmune | Demonstrates autoantibody-mediated retinal damage | Inner retinal emphasis; not specific to annular pattern |
| Recoverin hybridoma Balb/cJ mice | Induced autoimmune | Shows photoreceptor/ONL damage more relevant to AAOR | Lacks annular spatial pattern; single antigen |
| CSF1R-antagonist light damage mice | Microglial depletion | Studies role of microglia in retinal degeneration | Mechanism (light) differs from autoimmune |
Lu et al. (2010, PMID: 21031137): - Recoverin-immunized LPR mice: B6.MRL-Fas(lpr)/J mice immunized with recombinant recoverin showed "swollen cell bodies in the inner nuclear layer," reduced ERG, and increased GFAP staining indicating Muller cell and astrocyte reactive gliosis - Recoverin hybridoma-injected Balb/cJ mice: "photoreceptor and outer nuclear layer swelling" with complement C1q and C3 deposits and "increased numbers of CD4+ and CD68+ cells from retinas" - Both models demonstrated "leukocyte invasion, complement deposition, reactive gliosis in the retina, and selective retinal degeneration"
Mouse autoimmune retinopathy models may be useful for: - Testing immunomodulatory therapies - Understanding photoreceptor autoimmune destruction mechanisms - Characterizing candidate retinal autoantigens
Fekrat et al. (2000) established AAOR as a specific clinical variant by describing four patients with "acute onset of visual field loss associated with a localized, white annular outer retinopathy" (PMID: 11078842). Monson & Smith (2011) subsequently compiled 131 AZOOR cases including AAOR, confirming: "predominantly white individuals, average age at presentation was 36.7 years, and the male:female ratio was 1:3.2" (PMID: 21056448). Chen et al. (2025) reported 9 AAOR patients (12 eyes) aged 18-39 years (PMID: 40446848), and Ramtohul et al. (2025) expanded the concept to 23 patients under "Acute Outer Retinopathy" (PMID: 40436146).
Chen et al. (2025) provided the first systematic staging: "The clinical course was subdivided acutely progressive stage (APS), stationary stage (SS) and atrophic stage (AS) (1-3 weeks, 3 weeks to 3 months and >3 months, respectively)" (PMID: 40446848). This staging framework enables clinicians to anticipate disease evolution and time interventions.
Ramtohul et al. (2025) provided the most robust data: "Presenting symptoms included photopsia (87%), blurred vision (57%), and scotoma (57%)" from 23 patients. They also identified the "angular sign of Henle fiber layer hyperreflectivity (ASHH)" as an important OCT biomarker (PMID: 40436146).
Herbort et al. (2021) established that "the primary damage was identified at the level of the photoreceptor outer segments with an intact choriocapillaris and retinal pigment epithelium (RPE) layer, these structures being only secondarily involved" (PMID: 34209956). Tagami et al. (2014) demonstrated autoantibodies targeting photoreceptors (PMID: 25266678). Seetharam et al. (2015) confirmed "hyperreflectivity in the outer nuclear layer and the Henle fiber layer along with marked atrophy of the outer retina within the white ring" (PMID: 25383859).
Chen et al. (2025): "Seven eyes of 5 patients showed no macular involvement with best corrected visual acuity (BCVA) of 20/20, while 5 eyes of 5 patients showed macular involvement with poorer BCVA of HM-20/400" (PMID: 40446848). Monson & Smith (2011): "Various treatments have been attempted in patients with AZOOR--including systemic corticosteroids, other systemic immunosuppressive agents, and different antimicrobials--but none have been proven effective" (PMID: 21056448). Bemme et al. (2016) reported anecdotal success: "further progression could be stopped by a combination of antiviral and immunosuppressive therapy" (PMID: 25930180).
| Paper | PMID | Contribution |
|---|---|---|
| Gass (1993) -- AZOOR original description | 8340485 | Described the AZOOR syndrome spectrum; 13 patients |
| Fekrat et al. (2000) -- Original AAOR description | 11078842 | First description of AAOR as a distinct entity; 4 patients |
| Monson & Smith (2011) -- Comprehensive review | 21056448 | Compiled 131 AZOOR/AAOR cases; demographics and prognosis |
| Mrejen et al. (2014) -- AZOOR imaging classification | 24945598 | Imaging-based AZOOR classification; trizonal pattern; 30 cases |
| Tagami et al. (2014) -- Autoimmune evidence | 25266678 | Antiretinal antibodies in all AZOOR patients tested |
| Seetharam et al. (2015) -- OCT characterization | 25383859 | Detailed OCT findings; photoreceptor restoration documented |
| Herbort et al. (2021) -- Pathology mechanism | 34209956 | Established photoreceptor-first pathology via multimodal imaging |
| Roy & Dutta Majumder (2024) -- Current understanding | 38454854 | Comprehensive review of AZOOR including AAOR variant |
| Chen et al. (2025) -- Clinical staging | 40446848 | First systematic staging of AAOR; 9 patients, 12 eyes |
| Ramtohul et al. (2025) -- Largest multicenter study | 40436146 | 23 patients, 38 eyes; symptom frequencies; ASHH sign |
Extremely small sample sizes: The largest AAOR-specific study includes only 23 patients. All evidence is Level 4 (case series) or Level 5 (case reports).
No molecular characterization of target antigens: The specific photoreceptor antigens targeted by autoantibodies in AAOR remain unidentified.
No genetic studies: No GWAS, exome sequencing, or candidate gene studies have been performed. HLA typing has not been systematically reported.
No controlled treatment trials: The extreme rarity precludes randomized controlled trials. All treatment evidence is anecdotal.
No tissue pathology: No histopathological or immunohistochemical analysis of AAOR retinal tissue has been published. All structural understanding derives from in vivo imaging.
Inconsistent nomenclature: The relationship between AAOR, AOR, AZOOR, and MORR remains debated, complicating literature synthesis.
No standardized diagnostic criteria: Diagnosis remains clinical and exclusionary, without formally validated criteria.
No biomarkers for prognosis: Beyond macular involvement on imaging, no molecular or imaging biomarkers predict which patients will progress.
Absence of formal QoL studies: No patient-reported outcome measures have been assessed.
No animal model specific to AAOR: Existing autoimmune retinopathy models do not recapitulate the annular spatial pattern.
Characterization of target autoantigens: Perform immunoprecipitation and mass spectrometry on sera from AAOR patients against retinal protein extracts to identify the specific photoreceptor antigens targeted.
HLA typing study: Collect HLA data from AAOR patients to identify susceptibility alleles, as done for other autoimmune ocular conditions (e.g., HLA-A29 in birdshot chorioretinopathy).
International registry: Establish a multicenter AAOR/AOR registry to accumulate sufficient patients for epidemiological and genetic analyses.
Standardized diagnostic criteria: Develop and validate formal diagnostic criteria using Delphi consensus methodology among retina specialists.
Longitudinal imaging biomarker study: Correlate baseline multimodal imaging features (FAF patterns, choroidal thickness, ellipsoid zone disruption extent) with long-term visual outcomes to develop prognostic biomarkers.
Aqueous humor proteomics: Analyze aqueous humor samples from AAOR patients for cytokine profiles and antibody characterization.
Pilot treatment study: Design a prospective, multicenter observational study comparing early immunosuppression versus observation, given the impossibility of a RCT.
Development of AAOR-specific animal model: Once target antigens are identified, immunize animal models with specific antigens to create a more faithful disease model.
Single-cell transcriptomics: If surgical biopsy becomes available, perform single-cell RNA sequencing to characterize the immune cell populations infiltrating affected retina.
Viral metagenomic analysis: Perform metagenomic sequencing on aqueous/vitreous samples during acute phase to identify potential viral triggers.
| Category | Terms |
|---|---|
| Disease | MONDO: not assigned; closest: AZOOR spectrum |
| Phenotypes (HPO) | HP:0030786 (Photopsia), HP:0000572 (Visual field defect), HP:0000575 (Scotoma), HP:0000505 (Visual impairment), HP:0000654 (Abnormal ERG), HP:0030624 (Abnormal FAF), HP:0030329 (Retinal thinning), HP:0000580 (Pigmentary retinopathy), HP:0030532 (Enlarged blind spot) |
| Anatomy (UBERON) | UBERON:0000966 (retina), UBERON:0001787 (photoreceptor layer), UBERON:0001782 (RPE), UBERON:0001776 (choroid), UBERON:0000019 (eye), UBERON:0001783 (optic disc), UBERON:0000053 (macula), UBERON:0001785 (fovea) |
| Cell Types (CL) | CL:0000604 (retinal rod cell), CL:0000573 (retinal cone cell), CL:0002586 (RPE cell), CL:0000636 (Mueller cell), CL:0000624 (CD4+ T cell), CL:0000235 (macrophage) |
| Biological Processes (GO) | GO:0006955 (immune response), GO:0006915 (apoptotic process), GO:0006958 (complement activation), GO:0007601 (visual perception), GO:0001750 (photoreceptor outer segment), GO:0001917 (photoreceptor inner segment) |
| Treatments (MAXO) | MAXO:0000756 (corticosteroid therapy), MAXO:0000757 (immunosuppressive therapy), MAXO:0001001 (antiviral therapy), MAXO:0001298 (intravitreal injection), MAXO:0001046 (biologic therapy), MAXO:0001305 (low vision rehabilitation), MAXO:0000540 (counseling) |
Report generated: 2026-05-05 | Based on review of 49 publications | 5 confirmed findings